ERBB2 and neoplasm: Trastuzumab and pertuzumab block HER2 dimerization and disrupt downstream signaling [130,131,137,138], while T-DM1 and T-DXd deliver cytotoxic payloads selectively into HER2-expressing tumor cells [132,133,134,135,136,139,140,141] (Figure 2B).